Neuromyelitis optica spectrum disorder in patients with connective tissue disease and myelitis

Arthritis Care and Research

Volumn 63, Issue 8, 2011, Pages 1203-1208

  Kolfenbach, Jason R ^a   Horner, Brian J ^a   Ferucci, Elizabeth D ^b   West, Sterling G ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; MYCOPHENOLIC ACID; PHOSPHOLIPID ANTIBODY; RHEUMATOID FACTOR; RITUXIMAB; STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE MYELITIS; CLINICAL ARTICLE; CLONUS; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DRUG MEGADOSE; FECES INCONTINENCE; FEMALE; HUMAN; HYPERREFLEXIA; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MALE; MONOTHERAPY; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROMYELITIS OPTICA SPECTRUM DISORDER; OPTIC NEURITIS; PLASMAPHERESIS; SEROLOGY; SJOEGREN SYNDROME; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; URINE RETENTION;

ADOLESCENT; ADULT; AGED; AUTOIMMUNE DISEASES; COHORT STUDIES; CONNECTIVE TISSUE DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYELITIS; NEUROMYELITIS OPTICA; PATIENT CARE PLANNING; RISK FACTORS; YOUNG ADULT;

EID: 84860389217     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20486     Document Type: Article

References (46)

1. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12. (Pubitemid 39626806)
2. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 2008;10:55-66. (Pubitemid 351176056)
3. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003;60:848-53. (Pubitemid 36297372)
4. McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Hinson SR, Kryzer TJ, et al. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol 2009;66:1134-8.
5. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59:566-9. (Pubitemid 43358081)
6. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008;70:2197-200.
7. Birnbaum J, Kerr D. Devic's syndrome in a woman with systemic lupus erythematosus: diagnostic and therapeutic implications of testing for the neuromyelitis optica IgG autoantibody. Arthritis Rheum 2007;57:347-51. (Pubitemid 47164100)
8. Kim SM, Waters P, Vincent A, Kim SY, Kim HJ, Hong YH, et al. Sjogren's syndrome myelopathy: spinal cord involvement in Sjogren's syndrome might be a manifestation of neuromyelitis optica. Mult Scler 2009;15:1062-8.
9. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002;59:499-505.
10. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
11. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8. (Pubitemid 34539104)
12. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9. (Pubitemid 43958540)
13. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-15. (Pubitemid 47238676)
14. Mok CC, To CH, Mak A, Poon WL. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol 2008;35:172-4.
15. Gibbs AN, Moroney J, Foley-Nolan D, O'Connell PG. Neuromyelitis optica (Devic's syndrome) in systemic lupus erythematosus: a case report. Rheumatology (Oxford) 2002;41:470-1. (Pubitemid 34537851)
16. Hagiwara N, Toyoda K, Uwatoko T, Yasumori K, Ibayashi S, Okada Y. Successful high dose glucocorticoid treatment for subacute neuromyelitis optica with systemic lupus erythematosus. Intern Med 2005;44:998-1001. (Pubitemid 41644105)
17. Jacobi C, Stingele K, Kretz R, Hartmann M, Storch-Hagenlocher B, Breitbart A, et al. Neuromyelitis optica (Devic's syndrome) as first manifestation of systemic lupus erythematosus. Lupus 2006;15:107-9. (Pubitemid 43345337)
18. Barroso B. Primary Sjogren's syndrome mimicking neuromyelitis optica. Eur J Intern Med 2007;18:507. (Pubitemid 47385850)
19. Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008;65:78-83.
20. Birnbaum J, Kerr D. Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. Nat Clin Pract Rheumatol 2008;4:381-6. (Pubitemid 351974010)
21. Javed A, Balabanov R, Arnason BG, Kelly TJ, Sweiss NJ, Pytel P, et al. Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler 2008;14:809-14.
22. Min JH, Kim HJ, Kim BJ, Lee KW, Sunwoo IN, Kim SM, et al. Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica. Mult Scler 2009;15:1069-76.
23. Nasir S, Kerr DA, Birnbaum J. Nineteen episodes of recurrent myelitis in a woman with neuromyelitis optica and systemic lupus erythematosus. Arch Neurol 2009;66:1160-3.
24. Birnbaum J, Petri M, Thompson R, Izbudak I, Kerr D. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum 2009;60:3378-87.
25. Kato H, Ichikawa H, Hayashi D, Yamazaki T, Ohnaka Y, Kawamura M. A 25-year-old woman with primary Sjogren syndrome who developed optic neuritis and encephalomyelitis associated with an anti-aquaporin 4 antibody. Rinsho Shinkeigaku 2009;49:576-81. In Japanese.
26. Rabadi MH, Kundi S, Brett D, Padmanabhan R. Neurological pictures: primary Sjogren syndrome presenting as neuromyelitis optica. J Neurol Neurosurg Psychiatry 2010;81:213-4.
27. Imbe H, Nakajima H, Ito T, Kitaoka H. Neuromyelitis optica in a patient with Sjogren syndrome with distal renal tubular acidosis: case report. Rinsho Shinkeigaku 2010;50:168-71. In Japanese.
28. Sergio P, Mariana B, Alberto O, Claudia U, Oscar R, Pablo M, et al. Association of neuromyelitis optic (NMO) with autoimmune disorders: report of two cases and review of the literature. Clin Rheumatol 2010;29:1335-8.
29. Chourkani N, El Moutawakil B, Sibai M, Bourezgui M, Rafai MA, Slassi I. Primary Sjogren's syndrome and neuromyelitis optica. Rev Med Interne 2010;31:e13-5. In French.
30. Kahlenberg JM. Neuromyelitis optica spectrum disorder as an initial presentation of primary Sjogren's syndrome. Semin Arthritis Rheum 2010;40:343-8.
31. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-69. (Pubitemid 27493740)
32. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964-8. (Pubitemid 44036298)
33. Bot JC, Barkhof F, Polman CH, Lycklama a Nijeholt GJ, de Groot V, Bergers E, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004;62:226-33. (Pubitemid 38167129)
34. Tellez-Zenteno JF, Remes-Troche JM, Negrete-Pulido RO, Davila-Maldonado L. Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six cases. Lupus 2001;10:851-6. (Pubitemid 34019215)
35. Sofat N, Venables PJ. Is Sjogren myelopathy Devic disease? Ann Rheum Dis 2008;67:730-1.
36. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005;62:865-70. (Pubitemid 40973448)
37. Zavada J, Nytrova P, Wandinger KP, Radka S, Putova I, Tegzova D, et al. Seroprevalence of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus [abstract]. Arthritis Rheum 2010;62 Suppl: S492.
38. Wandinger KP, Stangel M, Witte T, Venables P, Charles P, Jarius S, et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren's syndrome. Arthritis Rheum 2010;62:1198-200.
39. Birnbaum J, Kerr D, Baer AN. Clinical, radiographic, and autoantibody features are associated with distinct patterns of demyelinating syndromes in Sjogren's patients [abstract]. Arthritis Rheum 2009;60 Suppl: S187.
40. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007;13:128-32. (Pubitemid 46152772)
41. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51:1219-20. (Pubitemid 28473439)
42. Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007;13:968-74. (Pubitemid 351541430)
43. Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66:1128-33.
44. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270-2.
45. Aho K, Palosuo T, Raunio V, Puska P, Aromaa A, Salonen JT. When does rheumatoid disease start? Arthritis Rheum 1985;28:485-9. (Pubitemid 15109897)
46. Majka DS, Deane KD, Parrish LA, Lazar AA, Baron AE, Walker CW, et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis 2008;67:801-7. (Pubitemid 351829380)